

SBUHB Advanced therapy pathway for Axial Spondyloarthritis

SPECIAL CONSIDERATIONS

*The choice of treatment should be made after discussion between the clinician and the patient about the advantages and disadvantages of the treatments available. This may include considering associated conditions such as extra-articular manifestations. If more than 1 treatment is suitable, the least expensive (taking into account administration costs and patient access schemes) should be chosen.

* An alternative first-line may be chosen in specific patient circumstances, the reason for choosing an alternative must be documented in the patient record. In particular, consider Benepali for those with higher risk of infection or TB reactivation.

Consider dose tapering the biologic in patients in persistent remission.

Sequential use of up to 4 biologics in non-responders is permissible, beyond this approval of Clinical lead required.

Prescribe drugs available as biosimilar by brand.

In primary non-responders consider a biologic with different mechanism of action.

